Earnings ·
Genmab A/S reported first-half 2026 revenue of $2,051 million, a 25% increase from the prior year period
GNMSFGenmab A/S
Genmab A/S reported first-half 2026 revenue of $2,051 million, a 25% increase from the prior year period. Royalty revenue rose to $1,708 million, driven by higher DARZALEX and Kesimpta sales, while EPKINLY net product sales reached $312 million. The company announced positive Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma. Genmab updated its full-year 2026 guidance, raising the revenue midpoint to $4,425 million and adjusted operating profit midpoint to $1,225 million due to stronger royalty and product sales expectations. The firm operates in the biotechnology industry, developing and commercializing antibody-based therapies for cancer and autoimmune diseases.